Concordia Healthcare Corp., of Oakville, Ontario, said its subsidiary Pinnacle Biologics Inc. enrolled the first patients in a randomized phase II trial to evaluate Photodynamic Therapy with Photofrin for patients with epithelioid malignant pleural mesothelioma.